Latest Manufacturing News

First Graphene Limited has reported a landmark quarter with a 156% surge in customer cash receipts and a major industrial-scale production of graphene-enhanced cement, signalling a pivotal step in commercialising graphene across multiple sectors.

Aurora Labs has marked a significant milestone by securing its first purchase order for micro gas turbine engines, alongside strategic MOUs with major defence groups and a $5.5 million capital raise to fuel growth.

Nexsen Limited has reported significant progress in its rapid diagnostic technologies, including a key FDA pre-submission for its GBS rapid sensor and a solid cash reserve post-IPO to support commercialisation efforts.

Skin Elements Limited has marked a pivotal quarter with a $2.5 million capital raise and successful product evaluations, setting the stage for commercial rollout of its natural biotechnology range in 2026.

Liberty Metals has completed the acquisition of a 100% interest in a suite of Brazilian critical minerals projects, marking a significant strategic expansion into titanium and rare earth elements. The company also rebranded and initiated exploration programs to unlock value in these high-potential assets.

Orbital Corporation Ltd reports a stronger cash position and a strategic new order for its 350cc heavy fuel engine, signalling growth in both military and commercial UAV markets.

Jatcorp Limited reported a striking 165% revenue increase in Q2 FY26, driven by strong demand in Australia, Hong Kong, and China. The company also secured $4.2 million through an entitlement offer to support its growth ambitions across Southeast Asia.

Aeris Environmental Ltd has reported strong commercial momentum with its Syncromesh IoT platform and specialty chemicals, highlighted by initial orders from Budweiser APAC and a growing purchase order pipeline exceeding $800,000.

Avecho Biotechnology is on the cusp of completing patient dosing in its pivotal Phase III CBD insomnia trial, backed by a recent $2.5 million capital raise and patent allowances in the US and Europe.

InhaleRx Limited has progressed its clinical trials for three drug candidates targeting cancer pain, panic disorder, and treatment-resistant depression, while securing additional funding and preparing for a company rebrand.

Inhalerx Limited reported a $628,000 cash burn in the December quarter while securing substantial funding facilities to advance its clinical trials. The company’s cash position and financing arrangements suggest a runway extending over 80 quarters at current spending levels.

Energy Technologies Limited has significantly improved its cash flow position in the December 2025 quarter, reducing cash outflows by over a third while raising additional debt funding to support working capital.